GLAXOSMITHKLINE PLC Form 6-K October 10, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending October 2014

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

_

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 9 October 2014 that the following Directors, Persons Discharging Managerial Responsibility and Connected Person acquired GSK Ordinary Shares ('Shares') on 9 October 2014, at a price of 1400.26 pence per Ordinary Share, through GSK's ShareReward Plan (the 'Plan'):

Director/PDMR	Number of Shares under the personal contribution element of the plan	Number of Shares under the matching element of the plan (GSK contribution)		
Sir Andrew Witty	9	9		
Mr R G Connor	9	9		
Mr S Dingemans	9	9		
Mr D S Redfern	9	9		
Ms C Thomas	9	9		
Mr P C Thomson	9	9		
Dr P J T Vallance	9	9		
Ms E Walmsley	9	9		
Mrs V A Whyte	9	9		

Connected person	Number of Shares	Number of Shares			
	under the personal	under the matching			
	contribution element	contribution element of element of the plan			
	the plan	(GSK contribution)			
Mrs K Thomson	1	1			

(Connected person of Mr

P C Thomson)

V A Whyte Company Secretary 10 October 2014

SIGNATURES

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange	ge Act of 1934,	the registrant h	nas duly cause	ed this report to	be)
signed on its behalf by the undersigned, thereunto duly	authorised.				

GlaxoSmithKline plc (Registrant)

Date: October 10, 2014

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc